环氧化酶-2的表达是结肠直肠癌晚期复发的预测指标

表1

376例R0切除术后COX-2表达的临床和病理特征。


变量	总病人()	cox - 2 - ()	cox - 2阳性()	价值

年龄(岁)				0.496
< 70	311例(82.7%)	134例(81.2%)	177例(83.9%)
≥70	65例(17.3%)	31 (18.8%)	34 (16.1%)
性别				0.436
男性	208例(55.3%)	95例(57.6%)	113例(53.6%)
女	168例(44.7%)	70例(42.4%)	98例(46.4%)
肿瘤的位置				0.209
右结肠	82例(21.8%)	34 (20.6%)	48 (22.7%)
左结肠	113例(30.1%)	43 (26.1%)	70例(33.2%)
直肠	181例(48.1%)	88例(53.3%)	93例(44.1%)
肿瘤大小				0.961
< 5厘米	118例(31.4%)	52 (31.5%)	66例(31.3%)
≥5厘米	258例(68.6%)	113例(68.5%)	145例(68.7%)
生产总值(gdp)类型				0.297
Fungating	180例(44.9%)	83例(50.3%)	97例(46.0%)
渗透性的	170例(46.9%)	69例(41.8%)	101例(47.8%)
未知的	26 (8.2%)	13 (7.9%)	13 (6.2%)
细胞类型				0.303
Nonmucinous	356例(94.7%)	154例(93.3%)	202例(95.7%)
粘液性	20 (5.3%)	11 (6.7%)	9 (4.3%)
分化				0.032
WD	10 (2.7%)	5 (3.0%)	5 (2.4%)
医学博士	301例(80.1%)	141例(85.5%)	160例(75.8%)
PD	65例(17.3%)	19 (11.5%)	46 (21.8%)
淋巴入侵				0.004
缺席	180例(47.9%)	65例(39.4%)	115例(54.5%)
现在	196例(52.1%)	100例(60.6%)	96例(45.5%)
血管侵犯				0.634
缺席	372例(98.9%)	164例(99.4%)	208例(98.6%)
现在	4 (1.1%)	1 (0.6%)	3 (1.4%)
T类别				0.089
T1	7 (1.9%)	1 (0.6%)	6 (2.8%)
T2	32 (8.5%)	9 (5.5%)	23 (10.9%)
T3	330例(87.8%)	152例(92.1%)	178例(84.4%)
T4	7 (1.9%)	3 (1.8%)	4 (1.9%)
N类别				0.019
N0	185例(49.2%)	69例(41.8%)	116例(55.0%)
N1	90例(23.9%)	41 (24.8%)	49 (23.2%)
N2	101例(26.9%)	55 (33.3%)	46 (21.8%)
阶段				0.003
我	31 (8.2%)	7 (4.2%)	24 (11.4%)
2	158例(42.0%)	62例(37.6%)	96例(45.5%)
3	187例(49.7%)	96例(58.2%)	91例(43.1%)
递归式				0.001
早期(≤3岁)	71例(18.9%)	45 (27.4%)	26 (12.3%)
晚(> 3年)	27 (7.2%)	7 (4.3%)	20 (9.4%)
没有	278例(73.9%)	112例(67.9%)	166例(78.7%)

胃肠病学研究与实践

环氧化酶-2的表达是结肠直肠癌晚期复发的预测指标

表1